¼¼°èÀÇ ¹æ»ç¼± Ä¡·áÇÐ ½ÃÀå
Radiotheranostics
»óǰÄÚµå : 1644234
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 168 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹æ»ç¼± Ä¡·áÇÐ ½ÃÀåÀº 2030³â±îÁö 224¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 104¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¹æ»ç¼± Ä¡·áÇÐ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 13.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 224¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠǥÀû Áø´Ü ¸ð´Þ¸®Æ¼´Â CAGR 7.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 98¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç¥Àû Ä¡·áÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 20.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 27¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹æ»ç¼± Ä¡·áÇÐ ½ÃÀåÀº 2024³â¿¡ 27¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 35¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 11.7%¿Í 12.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹æ»ç¼± Ä¡·áÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹æ»ç¼± Ä¡·áÇÐÀ» Á¤¹ÐÀÇ·áÀÇ ÃÖÀü¼±À¸·Î ²ø¾î¿Ã¸° ¿äÀÎÀº ¹«¾ùÀΰ¡?

¿µ»ó Áø´Ü°ú Ç¥Àû ¹æ»ç¼± Ä¡·á¸¦ °áÇÕÇÑ ÃÖ÷´Ü Á¢±Ù ¹æ½ÄÀÎ ¹æ»ç¼± Ä¡·á´Â ¸ÂÃãÇü ÀÇ·áÀÇ °ÔÀÓ Ã¼ÀÎÀú·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÀÌÁß ±â´É ±â¼úÀº Á¾¾çÀÇ Á¤È®ÇÑ ½Äº°°ú ¹æ»ç¼º ÀǾàǰÀ» ÀÌ¿ëÇÑ ¸ÂÃãÇü Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, ¹æ»ç¼± Ä¡·á´Â º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹æ»ç¼± Ä¡·á¿Í ÇÙÀÇÇÐÀÇ ÅëÇÕÀº Á¾¾çÇп¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ È¯Àڵ鿡°Ô ´õ ³ªÀº Ä¡·á °á°ú¿Í »îÀÇ ÁúÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ¸é¼­ ¹æ»ç¼± Ä¡·á´Â ¾Ï°ú ½Î¿ì´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¹æ»ç¼± Ä¡·áÇÐÀÇ ¹üÀ§¸¦ ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ¹æ»ç¼± Ä¡·áÀÇ ¿ª·®À» È®ÀåÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ·çÅׯ¬-177À̳ª ¾ÇƼ´½-225¿Í °°Àº ¹æ»ç¼ºµ¿À§¿ø¼Ò¿Í °°Àº »õ·Î¿î ¹æ»ç¼º ÀǾàǰÀÇ °³¹ßÀº ¿µ»ó Áø´Ü°ú Ä¡·á ¸ðµÎ¿¡¼­ ´õ ³ôÀº Á¤È®µµ¸¦ °¡´ÉÇÏ°Ô Çϰí, PET/CT³ª SPECT/CT¿Í °°Àº ºÐÀÚ À̹Ì¡ ±â¼úÀÇ ¹ßÀüÀº Áúº´ Áø´Ü°ú Ä¡·á ¸ð´ÏÅ͸µÀÇ Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÌ ¹æ»ç¼± Ä¡·á ¿öÅ©Ç÷ο쿡 ÅëÇյǾî À̹ÌÁö ÇØ¼®À» °­È­Çϰí Ä¡·á °èȹÀ» ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÓ»óÀû ¼º°øÀ» ÃËÁøÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÌ ¹æ»ç¼± Ä¡·áÇÐ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù.

¹æ»ç¼± Ä¡·áÇÐÀÇ »õ·Î¿î ÀÀ¿ë ¹× µ¿ÇâÀº?

Àü¸³¼±¾Ï°ú ½Å°æ³»ºÐºñÁ¾¾ç Ä¡·á¿¡ Å« ¼º°øÀ» °ÅµÐ Á¾¾çÇÐ ºÐ¾ß ¿Ü¿¡µµ ¹æ»ç¼± Ä¡·áÀÇ ¿ëµµ°¡ ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ƯÁ¤ »ý¹°ÇÐÀû °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï´Â ´É·ÂÀ» Ȱ¿ëÇÏ¿© ½ÉÇ÷°ü°è ÁúȯÀ̳ª ƯÁ¤ °¨¿°¼º Áúȯ°ú °°Àº ´Ù¸¥ Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î µ¿ÇâÀ¸·Î´Â ¸é¿ª¿ä¹ýÀ̳ª È­Çпä¹ý°ú °áÇÕÇÏ¿© Ä¡·á È¿°ú¸¦ ³ôÀÌ´Â º´¿ë¿ä¹ýÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹æ»ç¼º ÀǾàǰ »ý»ê ¹× °ø±Þ¸Á ¹°·ùÀÇ ¹ßÀüÀº È®À强 ¹®Á¦¸¦ ÇØ°áÇÏ°í ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ÀÌ·¯ÇÑ Ä¡·á¹ýÀÌ ´õ ¸¹Àº ȯÀڵ鿡°Ô Á¦°øµÉ ¼ö ÀÖµµ·Ï º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¹æ»ç¼± Ä¡·áÇÐ ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

¹æ»ç¼± Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹æ»ç¼± Ä¡·á´Â Áß¿äÇÑ °ü½É ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼º ÀǾàǰ °³¹ß ¹× ºÐÀÚ À̹Ì¡ ±â¼úÀÇ »ó´çÇÑ ¹ßÀüÀº ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ È¿°ú¿Í Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÇÙÀÇÇÐ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ½ÅÈï ±¹°¡ ½ÃÀåÀÇ ÀÇ·á ¿¹»ê È®´ëµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ ¹× ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ »çÀÌ¿¡¼­ °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù ¹æ½ÄÀ» ¼±È£ÇÏ´Â °æÇâÀÌ ³ô¾ÆÁö¸é¼­ ¹æ»ç¼± Ä¡·áÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ÀÌ À¯¸ÁÇÑ ±â¼úÀÇ º¸±Þ¿¡ ´õ¿í ±â¿©Çϰí ÀÖÀ¸¸ç, Á¤¹ÐÀÇ·áÀÇ ¹Ì·¡¿¡¼­ ±× ¿ªÇÒÀ» È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾ç½Ä(Ç¥ÀûÁø´ÜÁ¦, Ç¥ÀûÄ¡·áÁ¦); & ¹æ»ç¼ºµ¿À§¿ø¼Ò(·çÅׯ¬-177 ¹æ»ç¼ºµ¿À§¿ø¼Ò, °¥·ý-68 ¹æ»ç¼ºµ¿À§¿ø¼Ò, ¿ä¿Àµå-131 ¹æ»ç¼ºµ¿À§¿ø¼Ò, ¿ä¿Àµå-123 ¹æ»ç¼ºµ¿À§¿ø¼Ò, ±âŸ ¹æ»ç¼ºµ¿À§¿ø¼Ò); & ¿ëµµ(Á¾¾çÇÐ ÀÀ¿ë, ºñÁ¾¾çÇÐ ÀÀ¿ë, ºñÇ×¾Ï ÀÀ¿ë) Á¾¾çÇÐ ÀÀ¿ë, ºñÁ¾¾çÇÐ ÀÀ¿ë, Á¾¾çÇÐ ÀÀ¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 36»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Radiotheranostics Market to Reach US$22.4 Billion by 2030

The global market for Radiotheranostics estimated at US$10.4 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Targeted Diagnostics Modality, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Targeted Therapeutics Modality segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.0% CAGR

The Radiotheranostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Radiotheranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â